- Home
- RNG vs MIRM Comparison
RNG vs MIRM Comparison
Compare RNG & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNG
- MIRM
- Stock Information
- Founded
- RNG 1999
- MIRM 2018
- Country
- RNG United States
- MIRM United States
- Employees
- RNG N/A
- MIRM N/A
- Industry
- RNG EDP Services
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- RNG Technology
- MIRM Health Care
- Exchange
- RNG Nasdaq
- MIRM Nasdaq
- Market Cap
- RNG 3.0B
- MIRM 2.5B
- IPO Year
- RNG 2013
- MIRM 2019
- Fundamental
- Price
- RNG $28.97
- MIRM $52.45
- Analyst Decision
- RNG Buy
- MIRM Strong Buy
- Analyst Count
- RNG 13
- MIRM 11
- Target Price
- RNG $38.69
- MIRM $57.00
- AVG Volume (30 Days)
- RNG 1.2M
- MIRM 548.9K
- Earning Date
- RNG 02-20-2025
- MIRM 02-26-2025
- Dividend Yield
- RNG N/A
- MIRM N/A
- EPS Growth
- RNG N/A
- MIRM N/A
- EPS
- RNG N/A
- MIRM N/A
- Revenue
- RNG $2,400,395,000.00
- MIRM $307,028,000.00
- Revenue This Year
- RNG $9.97
- MIRM $83.04
- Revenue Next Year
- RNG $7.35
- MIRM $27.22
- P/E Ratio
- RNG N/A
- MIRM N/A
- Revenue Growth
- RNG 8.99
- MIRM 112.14
- 52 Week Low
- RNG $26.98
- MIRM $23.14
- 52 Week High
- RNG $42.19
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- RNG 26.58
- MIRM 64.07
- Support Level
- RNG $33.53
- MIRM $51.02
- Resistance Level
- RNG $35.25
- MIRM $53.76
- Average True Range (ATR)
- RNG 1.27
- MIRM 2.04
- MACD
- RNG -0.49
- MIRM 0.03
- Stochastic Oscillator
- RNG 10.29
- MIRM 73.31
About RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.